OCT 16, 2018 10:00 PM PDT

Potential Targeted Treatment for Crohn Disease

WRITTEN BY: Nouran Amin

Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract.

Now, recent research at Cornell University and University of North Carolina (UNC) is a step closer to advancing drug treatments for CD patients. Such research proposes the potential targeting of a key molecule, called microRNA-31 (miR-31), which can predict if a patient has subtype 1 or subtype 2 of Crohn’s disease. This is particularly crucial because patients with subtype 1, unlike subtype 2, will often not respond to treatments which can lead to the surgical interventions for strictures – the extreme narrowing of the gut. With clinical markers like miR-31, healthcare providers may be able to better asses a CD patient if they should consider pre-emptive surgery before the condition worsens.

“We are not at the point at which we are able to perform personalized medicine on this, but at the very least we think it can lead to better clinical trial designs,” says Praveen Sethupathy, senior co-author of the study.

Previously, clinical trials assessing a new drug for CD has grouped all patients together causing inconsistent results. However, using miR-31, scientists are now able to separate individuals with CD into subtypes for better drug assessment. The results of the study published in the journal JCI Insight.

Credit: Drug Target Review

“Our study hints that it’s not only that miR-31 could be a predictive indicator of clinical outcome, but also that it could be functionally relevant in driving the disease,” explains Sethupathy.

Researchers are now hopeful for future studies that will determine the exact role of miR-31 in gut biology. “Our long-term goal, extending the work of this study, is to better understand at the molecular level why CD is so different in its presentation across patients, and to use this knowledge to develop more effective therapies,” says Terrence Furey, an associate professor of genetics.

Source: Drug Target Review

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
FEB 10, 2021
Cannabis Sciences
Cannabis Lowers Blood Pressure in Older Adults
FEB 10, 2021
Cannabis Lowers Blood Pressure in Older Adults
Researchers from Ben-Gurion University of the Negev (BGU) in Israel have found that medical cannabis may reduce blood pr ...
FEB 11, 2021
Drug Discovery & Development
Antibiotic-Use During Pregnancy
FEB 11, 2021
Antibiotic-Use During Pregnancy
A study published in the Archives of Disease in Childhood, shows that fetal exposure to antibiotics in mid to late pregn ...
MAR 04, 2021
Infographics
All You Need to Know about COVID-19 Vaccines
MAR 04, 2021
All You Need to Know about COVID-19 Vaccines
After over a year lockdowns brought on by the pandemic, hopes for returning to something even similar to ' ...
MAR 16, 2021
Drug Discovery & Development
Machine Learning Speeds Up Drug Discovery
MAR 16, 2021
Machine Learning Speeds Up Drug Discovery
How do drugs work? Well, they work when they stick to their target protein. Of course, there is much more complicated pr ...
APR 17, 2021
Drug Discovery & Development
Nanofiber-Based Drug Treats Inflammation
APR 17, 2021
Nanofiber-Based Drug Treats Inflammation
Researchers at Duke University worked on creating a self-assembling nanomaterial-based drug that can help address damage ...
APR 22, 2021
Drug Discovery & Development
New Method To Fast Track Drug Development
APR 22, 2021
New Method To Fast Track Drug Development
The time it takes to respond to disease outbreaks is critical. But designing drugs to combat these disease outbreaks is ...
Loading Comments...